Therapeutic potential of icatibant (HOE-140, JE-049)

Expert Opinion on Pharmacotherapy
Nicholas L M Cruden, David E Newby

Abstract

There is now a substantial body of work implicating bradykinin, an endogenous peptide neurohormone, in the pathophysiology of a variety of inflammatory conditions in man. Icatibant (HOE-140, JE-049), a highly selective antagonist at the bradykinin B2 receptor, blocks the vasodilatation and increased vascular permeability associated with exogenous bradykinin administration both in experimental models and in vivo in man. Recent attention has focused on the therapeutic potential of icatibant in a number of human disease states. The most promising of these is hereditary angioedema in which Phase III clinical trials have recently been completed and regulatory approval is currently being sought in Europe and the USA. A therapeutic role for icatibant has also been proposed in several other human conditions including drug-induced angioedema, airways disease, thermal injury, refractory ascites in patients with liver cirrhosis, and acute pancreatitis, although this work remains largely experimental.

References

Mar 1, 1991·British Journal of Pharmacology·F J HockJ Knolle
Mar 1, 1991·British Journal of Pharmacology·K WirthJ Knolle
Feb 1, 1991·British Journal of Pharmacology·F LembeckJ Knolle
Jan 1, 1989·Clinical Immunology and Immunopathology·A P KaplanB Zweiman
Jun 1, 1973·The Journal of Clinical Investigation·A D SchreiberK F Austen
May 5, 1983·The New England Journal of Medicine·M SchapiraR W Colman
Jul 1, 1995·Canadian Journal of Physiology and Pharmacology·D ProudR M Naclerio
Apr 1, 1996·Journal of Cardiovascular Pharmacology·M FélétouE Canet
Jun 1, 1996·Immunopharmacology·M SiebeckJ C Cheronis
Sep 12, 1998·Lancet·J NussbergerA Agostoni
Dec 10, 1999·The Journal of Allergy and Clinical Immunology·J NussbergerA Agostoni
Dec 22, 1999·Immunopharmacology·A AgostoniJ Nussberger
Oct 31, 2000·Cardiovascular Research·P G McLeanA Ahluwalia
Sep 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Giuseppe MolinaroAlbert Adam
Sep 24, 2002·International Journal of Cardiology·Andrew J S Coats
Mar 18, 2003·International Immunopharmacology·Massimo CugnoAngelo Agostoni
Apr 24, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Nicholas L M CrudenDavid E Newby
Jan 29, 2005·British Journal of Clinical Pharmacology·M BasG Kojda
Aug 23, 2005·Journal of the American Academy of Dermatology·Allen P Kaplan, Malcolm W Greaves
Sep 24, 2005·Journal of Pharmacological Sciences·Marie Eve MoreauAlbert Adam
Nov 7, 2006·Immunology and Allergy Clinics of North America·James Brian ByrdNancy J Brown
Mar 1, 2007·Current Opinion in Critical Care·Joost W Schouten
Apr 10, 2007·The Journal of Allergy and Clinical Immunology·Konrad BorkWolfhart Kreuz
Jul 11, 2007·Allergy·M BasG Kojda
Jan 29, 2008·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Tom BowenZhi Yu Xiang
Apr 9, 2008·The Journal of Allergy and Clinical Immunology·Murat BasGeorg Kojda

❮ Previous
Next ❯

Citations

Feb 1, 2011·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·J Frank, P Poblete-Gutiérrez
Nov 4, 2005·Springer Seminars in Immunopathology·Marco CicardiBenedetta Cicardi
Nov 26, 2009·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Laurence BouilletAnne Gompel
Jul 30, 2010·Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology·Bruce L Zuraw
Nov 8, 2012·International Journal of Emergency Medicine·Jonathan A Bernstein, Joseph Moellman
Sep 23, 2010·Vascular Health and Risk Management·Hilary J Longhurst
May 21, 2011·Expert Review of Clinical Immunology·Laurence Bouillet
Sep 3, 2013·The Journal of Emergency Medicine·Lawrence M Lewis
May 26, 2012·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·I Del CorsoP Migliorini
Dec 27, 2011·The Journal of Allergy and Clinical Immunology·Teresa CaballeroUNKNOWN C-1-INH Deficiency Working Group
Jun 18, 2010·Journal of the American Academy of Dermatology·Peter W SchmidtFranz Trautinger
Mar 24, 2010·European Journal of Pharmacology·Stefania MeiniCarlo Alberto Maggi
May 19, 2009·European Journal of Pharmacology·Stefania MeiniCarlo Alberto Maggi
Apr 29, 2016·Expert Review of Clinical Pharmacology·Henriette Farkas
Oct 12, 2012·American Journal of Physiology. Cell Physiology·Marina DobrivojevićJochen R Hirsch
May 5, 2017·Frontiers in Endocrinology·Keren AsrafSigal Fleisher-Berkovich

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.